{"content":"<li class=\"n-box-item date-title\" data-end=\"1460865599\" data-start=\"1460779200\" data-txt=\"Sunday, December 22, 2019\">Saturday, April 16, 2016</li><li class=\"n-box-item sa-box-item\" data-id=\"3173493\" data-ts=\"1460824534\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CHMA\" target=\"_blank\">CHMA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3173493-fda-rejects-chiasmas-mycapssa-nda\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FDA rejects Chiasma&#39;s Mycapssa NDA</a></h4><ul>\n<li>Chiasma (NASDAQ:<a href=\"https://seekingalpha.com/symbol/CHMA\" title=\"Chiasma\">CHMA</a>) <a href=\"https://globenewswire.com/news-release/2016/04/15/829428/0/en/FDA-Issues-Complete-Response-Letter-for-Mycapssa-New-Drug-Application.html\" target=\"_blank\">receives </a>a Complete Response Letter (CRL) from the FDA regarding its New Drug Application seeking approval of lead product candidate and Orphan Drug-tagged <a href=\"http://www.chiasmapharma.com/octreotide-transformed\" target=\"_blank\">Mycapssa </a>(octreotide capsules) for the treatment of <a href=\"http://www.niddk.nih.gov/health-information/health-topics/endocrine/acromegaly/Pages/fact-sheet.aspx\" target=\"_blank\">acromegaly</a>, a hormonal disorder that results from an excessive amount of growth hormone in the body.</li>\n<li>Management will host a conference call on Monday, April 18 at 8:30 am ET to discuss the situation.</li>\n<li>\n<strong>Update</strong>: In a <a href=\"https://www.sec.gov/Archives/edgar/data/1339469/000119312516543792/d172181dex992.htm\" target=\"_blank\">statement</a>, the company says the FDA advised it that its application, based on data from an open-label single-arm Phase study, failed to provide sufficient evidence of efficacy so another clinical trial will be required, specifically a randomized, double-blind, placebo-controlled study of sufficient duration to ensure that the control of disease activity is stable at the time the primary endpoint is assessed. The agency also advised Chiasma that certain deficiencies noted at one of its suppliers during an on-site inspection need to be resolved before approval. An End-of-Review meeting between the parties is the next step in order to clarify a path forward.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3173493\" data-linked=\"FDA rejects Chiasma&#39;s Mycapssa NDA\" data-tweet=\"$CHMA - FDA rejects Chiasma&#39;s Mycapssa NDA https://seekingalpha.com/news/3173493-fda-rejects-chiasmas-mycapssa-nda?source=tweet\" data-url=\"https://seekingalpha.com/news/3173493-fda-rejects-chiasmas-mycapssa-nda\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:35 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>34&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li>","count":1,"message":null,"success":true,"today":{"start":1576990800,"end":1577077199,"str":"Sunday, December 22, 2019"},"yesterday":{"start":1576904400,"end":1576990799}}